^
Association details:
| Biomarker: | FAT2 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer
Published date:
02/25/2022
Excerpt:
...the relationship between FAT1/2/3/4 mutations and efficacy of immunotherapy was explored in the Hellmann cohort consist of patients with NSCLC....Relative to patients with wildtype FAT2, those with mutant FAT2 in this data set tended to have a longer PFS (median, 23.0 vs 6.5 months; HR = .426; 95% CI: 0.203–0.894; P = .087, Figure 7A), higher BOR (Figure 7B, 75.0% vs 30.0%, χ2 = 6.259, P = .012), and DCB rate (Figure7C, 87.0% vs 44.0%, χ2 = 5.420, P = .019).
DOI:
https://doi.org/10.1177/10732748221076682
